Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com

Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

By Jared Kaltwasser

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com

FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg

Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

By Giuliana Grossi

June 12th 2025

AJMC

Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

By Brigham Walker, PhD
Lalan Wilfong, MD

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com

C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

By Jared Kaltwasser

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Panel Discussion: Defining Quality in Oncology: Is There a Common Ground?

January 27th 2015

Panel Discussion: Defining Quality in Oncology: Is There a Common Ground?

Although there have been some accusations of "cookbook medicine" with regards to measurement guidelines, panelists Dennis Scanlon, PhD, Jess DeMartino, PhD, Phyllis Torda, and Laura Long, MD, do see progress to remedy the situation and make guidelines more effective.

Payer Perspectives on the Role and Impact of QOPI Certification

January 27th 2015

Payer Perspectives on the Role and Impact of QOPI Certification

Although the healthcare industry values what it tends to measure, what is measured is not necessarily what should have the most value, according to John Fox, MD, senior medical director and associate vice president of medical affairs at Priority Health.

Panel Discussion: Perspectives on Economics and Outcomes of Community vs Hospital Oncology Practice

January 27th 2015

Panel Discussion: Perspectives on Economics and Outcomes of Community vs Hospital Oncology Practice

Education of both patients and providers will be necessary to temper expectations of cancer care treatment outcomes, according to panelists Ted Okon, BS, MBA, executive director of the Community Oncology Alliance, Debra Patt, MD, MPH, partner at Texas Oncology, and Stacie Dusetzina, PhD, assistant professor at the University of North Carolina, Chapel Hill.

Early Findings of the Oncology Patient-Centered Medical Home

January 27th 2015

Early Findings of the Oncology Patient-Centered Medical Home

One of the early findings from various oncology medical homes throughout the country was that they work, claimed Ted Okon, BS, MBA, executive director of the Coalition Oncology Alliance.

January 27th 2015

CUDC-101 Provides Encouraging Results in Phase 1 Head and Neck Cancer

The drug targets multiple proteins that are overexpressed in head and neck cancer, the study published in Clinical Cancer Research says.

January 26th 2015

Study Discovers Lack of Disease Awareness Among Women Diagnosed With Breast Cancer

The findings, published in the journal Cancer found that women diagnosed with breast cancer were not very aware of the disease characteristics such as tumor grade or stage. The researchers also found a bias based on the patient's race.

January 26th 2015

CAR T Cells and Bispecific Antibodies: A Double-Edged Sword?

Wile several big and small pharmaceutical companies have invested research efforts in developing these complex, and expensive, treatment regimens, early results from trials indicate safety issues.

January 25th 2015

ASCO Elects President for 2016-2017

Daniel F. Hayes, MD, FASCO, has been elected president of the American Society of Clinical Oncology.

January 24th 2015

Managed Care Minute: January 24, 2015

A one-minute look back at the week of January 19, 2015, in managed care, including Marilyn Tavenner's departure from CMS and oncology drug pricing.

January 23rd 2015

Bayer Wants Patient Engagement in Early Drug Development

Bayer is collaborating with MD Anderson in Texas to develop a questionnaire that will query a patient's disease-related symptoms, a step to include PROs in early drug development which could help reduce adverse effects in the final product.

Panel Discussion: Payer, Provider, and Patient Roles for Understanding the End-of-Life Care Equation: Cost vs Survival Time vs Quality of Life

January 23rd 2015

Panel Discussion: Payer, Provider, and Patient Roles for Understanding the End-of-Life Care Equation: Cost vs Survival Time vs Quality of Life

Amy Berman, BS, RN, Bruce Feinberg, DO, and Patti Forest, MD, MBA, sit on the first panel discussion at Patient-Centered Oncology Care 2015 and discuss advanced directives and end-of-life care.

Segment 7 - Final Thoughts About Which Patients, Which Drugs, and Which Treatment Timeline

January 23rd 2015

Segment 7 - Final Thoughts About Which Patients, Which Drugs, and Which Treatment Timeline

Segment 6 - Patient-Reported Outcomes and Other Important Measures

January 23rd 2015

Segment 6 - Patient-Reported Outcomes and Other Important Measures

Segment 5 - Surrogate End Points in Clinical Trials: The Right Information?

January 23rd 2015

Segment 5 - Surrogate End Points in Clinical Trials: The Right Information?

Segment 4 - Healthcare Policy: Its Impact on Innovation and Financial Waste

January 23rd 2015

Segment 4 - Healthcare Policy: Its Impact on Innovation and Financial Waste

Segment 3 - Justifying Costs: A Request for More Evidence

January 23rd 2015

Segment 3 - Justifying Costs: A Request for More Evidence

Segment 2 - Comparative Effectiveness Research and Innovation: Do They Clash?

January 23rd 2015

Segment 2 - Comparative Effectiveness Research and Innovation: Do They Clash?

Segment 1 - The Value of Innovation in Oncology Care

January 23rd 2015

Segment 1 - The Value of Innovation in Oncology Care

Making the Grade on Survivorship: How are Payers Performing?

January 23rd 2015

Making the Grade on Survivorship: How are Payers Performing?

As cancer care becomes more powerful and people survivor longer, cancer is becoming a chronic disease that patients need to learn how to live with and remain productive. Although the role of payers in survivorship isn't fully baked yet, there is more focus in the area, according to Ira Klein, MD, MBA, FACP, chief medical officer at Aetna.

When Is the Right Time for Palliative Care?

January 23rd 2015

When Is the Right Time for Palliative Care?

The Patient-Centered Oncology Care 2014 meeting started off with a talk by Marian Grant, DNP, RN, CRNP, of the University of Maryland School of Nursing, on the topic of palliative care. Although palliative care is appropriate for patients of all ages and in any stage of a serious illness and can be provided alongside curative or disease-modifying treatments, she says she often gets called in very late to offer palliative care to patients.

January 23rd 2015

Early Detection, Cutting Edge Treatments for Breast Cancer Patients

In 2 interviews with Physicians' Education Resource, LLC, award-winning journalist Joan Lunden and Patrick I. Borgen, MD, of Maimonides Medical Center in Brooklyn, NY, discuss breast cancer in advance of the 32nd Annual Miami Breast Cancer Conference.

January 23rd 2015

Vitiligo Could Be a Marker of Efficacy for Melanoma Drugs, Study Indicates

The retrospective analysis conducted in stage 3 and 4 immunotherapy-treated melanoma patients found that the development of vitiligo could serve as a clinical marker for effective antimelanoma immunity and improved clinical outcome.

January 23rd 2015

After Hep C, Express Scripts Aims to Influence Oncology Drug Costs

CMO Steven Miller has already started working with oncologists as the company plans the process of steering physicians to use preferred drugs.

January 22nd 2015

Telehealth Intervention Improved QoL Among Head and Neck Cancer Patients

A telehealth intervention experiment in head and neck cancer patients was found to relive some posttreatment distress symptoms.

January 22nd 2015

The Value of Ultrasound in Breast Cancer Detection

A study conducted in Connecticut showed that ultrasound identified an additional 3.2 women in a 1000 with breast cancer, following a negative mammogram. This has raised a debate on the utility of a screening ultrasound.

January 22nd 2015

Progesterone-Based Contraceptives May Increase the Risk of Gliomas: Danish Study

The study found an increased risk of cancer, contradicting some earlier evidence that suggests the opposite.

January 21st 2015

State of the Union Calls for More Investments in Personalized Medicine

Laura Joszt, MA

In Tuesday night's State of the Union address, President Barack Obama did not spend a lot of time discussing healthcare, but he did highlight medical research and a growing field of medicine by announcing his new Precision Medicine Initiative.

January 21st 2015

ASCO Announces Partner for Groundbreaking CancerLinQ Platform

Mary K. Caffrey

A major technical partner is announced for the long-awaited HIT initiative that will give oncologists a data-derived "second opinion" right from their desktops, with the earliest versions scheduled to come online this year.

January 21st 2015

Patient Navigation Programs a Tremendous Boost for Patient-Centered Care in Oncology

Karyl Blaseg, RN, MS, OCN, writes about the important role of patient navigators in preventing healthcare disparities and promoting patient-centered care among cancer patients.

January 21st 2015

Rigid Cancer Cells Prevent Metastasis, Study Finds

Existing cancer therapies are geared toward massacring tumor cells, but researchers propose a different strategy: subtly hardening cancer cells to prevent them from invading new areas of the body. They devised a way of screening compounds for the desired effect and have identified a compound that shows promise in fighting pancreatic cancer.

...

141 142 143 144 145 146 147 148 149

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions